Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization, and treatment

Current Opinion in Oncology

Volumn 12, Issue 4, 2000, Pages 368-377

  Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE;

ARTIFICIAL EMBOLISM; CANCER LOCALIZATION; CARCINOGENESIS; CARCINOID; CLINICAL FEATURE; ECTOPIC HORMONE PRODUCTION; HUMAN; LIVER TRANSPLANTATION; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYMPTOM; TREATMENT PLANNING; TUMOR GROWTH; ZOLLINGER ELLISON SYNDROME;

CARCINOID TUMOR; CARCINOMA, ISLET CELL; HUMANS; PANCREATIC NEOPLASMS;

EID: 0034502241     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200007000-00015     Document Type: Review

References (111)

1. Natural history of digestive endocrine tumors
2. Carcinoid tumors
3. Advances in digestive endocrine tumours
4. Carcinoid tumors: Current concepts in diagnosis and treatment
5. Review article: Current status of gastrointestinal carcinoids
6. Carcinoid syndrome: A statistical evaluation of 748 reported cases
7. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors
8. Pathobiology and classification of gut endocrine tumors
9. Surgical treatment of carcinoid tumours of the stomach and small intestine
10. Surgical treatment of gastrointestinal endocrine tumors
11. Pancreatic endocrine tumors and carcinoid tumors: Recent insiqhts from genetic and molecular biologic studies
12. New insights in genetics of digestive neuroendocrine tumors
13. Molecular aspects of the endocrine tumours of the pancreas and the gastrointestinal tract
14. Geneotype/phenotype correlations of MEN1 gene mutations in sporadic gastrinoma
15. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome
16. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms
17. Genetic alterations in gastrinomas: An analysis of p16/CDKN2A tumor suppressor gene
18. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: An analysis of p16/MTS1 tumor suppressor gene inactivation
19. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors
20. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene
21. Amplification of the HER-2/neu protooncogene in human endocrine tumors
22. Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors
23. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications
24. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
25. Positional cloning of the gene tor multiple endocrine neoplasia-Type 1
26. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas
27. Carcinoid tumors frequently display genetic abnormalities involving chromosome 11
28. Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas
29. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors
30. The p16INK4a/CDKN2A tumor suppressor and its relatives
31. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study
32. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome
33. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area
34. An analysis of 8305 cases of carcinoid tumors
35. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis
36. Prognostic criteria in nonfunctioning pancreatic endocrine tumours
37. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours
38. Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival
39. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
40. Bronchopulmonary carcinoids: An analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties
41. Carcinoids of the colon and ileocecal region: A statistical evaluation of 363 cases collected from the literature
42. Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: A comparative study between ordinary carcinoids and atypical varieties
43. Carcinoids of the small intestine: A statistical evaluation of 1102 cases collected from the literature
44. Carcinoids of the jejunum and ileum
45. A retrospective analysis of 1570 appendiceal carcinoids
46. Carcinoids of the rectum: An evaluation of 1271 reported cases
47. Vipoma/diarrheogenic syndrome: A statistical evaluation of 241 reported cases
48. Vasoactive intestinal polypeptide secreting islet cell tumors: A 15-year experience and review of the literature
49. The gastrinoma/Zollinger-Ellison syndrome: Statistical evaluation of a Japanese series of 359 cases
50. Glucagonomas/diabetico-dermatogenic syndrome (DDS): A statistical evaluation of 407 reported cases
51. Insulinomas/hypoglycemic syndrome: A statistical evaluation of 1085 reported cases of a Japanese series
52. Somatostatin receptor imaging and therapy of pancreatic endocrine tumors
53. Peptide therapy: Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists
54. Somatostatin receptor scintigraphy in gastronomas
55. Radiolabeled somatostatin analogue(s): Peptide receptor scintigraphy and radionuclide therapy
56. Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management
57. Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors
58. Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management
59. Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome
60. Clinical impact of somatostatin receptol scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors
61. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours
62. Specificity of somatostatin receptor scintigraphy: A prospective study and the effects of false positive localizations on management in patients with gastrinomas
63. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors
64. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen
65. The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma
66. Octreotide treatment of carcinoid syndrome: Analysis of published dose-titration data
67. Octreotide long-acting release (LAR): A review of its pharmacological properties and therapeutic use in the management of acromegaly
68. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome
69. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients
70. Overview of chronic diarrhea caused by functional neuroendocrine neoplasms
71. Long-acting formulations of somatostatin analogues
72. Consensus statement: Octreotide dose titration in secretory diarrhea: Diarrhea management consensus development panel
73. Sandostatin LAR: Pharmacodynamics, efficacy, and tolerability in acromegalic patients
74. Slow-release lanreotide treatment in endocrine gastrointestinal tumors
75. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours
76. Digestive endocrine tumor management: Medical advanced disease
77. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors
78. Endocrine neoplasms of the pancreas
79. Surgery to cure the Zollinger-Ellison syndrome
80. Surgery for the Zollinger-Ellison syndrome
81. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1
82. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease: Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both
83. Systemic chemotherapy of advanced digestive neuroendocrine tumours
84. Prognostic variables in patients with gastrointestinal carcinoid tumours
85. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours
86. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours
87. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects
88. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors
89. Single dose of octreotide stabilizes metastatic gastro-entero-pancreatic endocrine tumours
90. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors
91. Combination therapy with octreotide and α-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors
92. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
93. Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumol action
94. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors
95. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma
96. Embolization and chemoembolization therapy for neuroendocrine tumors
97. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors
98. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors
99. 1-octreotide in midgut carcinoid syndrome
100. 1]-octreotide in patients with neuroendocrine tumors
101. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
102. 3] octreotide as carriers for somatostatin receptor targeted scintigraphy and radionuclide therapy
103. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma
104. Cryotherapy for neuroendocrine liver metastases
105. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: A 31-case French multicentric report
106. Proceed with caution: Liver transplantation for metastatic neuroendocrine tumors
107. Liver transplantation for metastatic neuroendocrine carcinoma
108. Liver transplantation for metastatic neuroendocrine tumors
109. Results of liver transplantation for gastroenteropancreatic tumor metastases
110. Assessment of five-year experience with abdominal organ cluster transplantation
111. Abdominal multivisceral transplantation